Caren B. Les
The global market for DNA diagnostic technologies is expected to be worth $10.6 billion in 2008 and to rise to more than $20.1 billion by 2013, with a compound annual growth rate (CAGR) of 13.7 percent, according to a report from BCC Research of Wellesley, Mass.
The study describes the major technologies for analyzing DNA in a clinical setting and offers the current global market status for them, along with forecasts for growth over the next five years. DNA-based assays continue to move from research settings into the clinic and represent one of the fastest growing segments of diagnostics, according to the company. Biomarkers are becoming increasingly important, especially in the field of cancer research and treatment.
The value in USD millions of the global market for clinical DNA diagnostics is shown from 2005 through 2007 and is projected by technology segment for 2008 and 2013. Courtesy of BCC Research.
The polymerase chain reaction-based diagnostic assays segment held the largest share of the market in 2008 with an estimated value of $5.39 billion. The segment is expected to reach a value of nearly 9.5 billion in 2013, with a CAGR of 11.9 percent.
Representing the second largest segment is the DNA microarray diagnostic assays market, which in 2008 has an estimated value of $2.4 billion and is expected to experience a CAGR of 13.8 percent to reach $4.6 billion by 2013.
The fastest growing segment, lab-on-a-chip diagnostics, with an estimated value of $890 million in 2008, is expected to rise in 2013 to $2.1 billion, with a CAGR of 18.7 percent.
Valued at $1.9 billion in 2008, the in situ hybridization diagnostic assays market is projected to see a CAGR of 15.3 percent to reach $3.9 billion by 2013.
Compiled from primary and secondary data sources, the report, published in June 2008, is titled “DNA Diagnostics: Technologies and Global Markets” (Report code: BIO063A).